Prosthesis Mismatch in Supra and Intra Annular valves

The self-expandable valve was associated to lower prosthesis-patient mismatch (PPM) compared against the balloon expandable valve regardless annular area, according to this study soon to be published in J Am Coll Cardiol Intv. This difference was basically driven by patients with larger body surface area (>1.83m²).

Mismatch protésico en válvulas supra anulares y en válvulas intra anulares

Prosthesis mismatch has been associated to increased mortality after transcatheter aortic valve replacement (TAVR) and also after surgical valve replacement (SAVR).

Until recently there were no precise data on PPM frequency, let alone a comparison between supra-annular (self-expandable) and intra-annular (balloon expandable) valves. 

For this analysis, researchers included 757 patients between 2007 and 2017 treated with a self-expandable valve (CoreValve, Evolut R) and a balloon expandable valve (SAPIEN THV/XT/3).


Read also: Discordance Between FFR and iFR. Which Measurement Is More Important?


The mismatch was classified −according to discharge effective orifice area indexed to body surface area−  into severe (<0.65 cm²/m²) or moderate (0.65 to 0.85 cm²/m²) for the general population and into severe (<0.60 cm²/m²) or moderate (0.60 to 0.90 cm²/m²) for the obese population (body mass index ≥30kg/m²).

Propensity score was used to compare both populations, with 224 pairs of patients with similar baseline characteristics.

At discharge, the self-expandable prosthesis presented a much lower mismatch incidence compared against the balloon expandable valve (mismatch 33.5% vs. 46.9%, p=0.004; severe mismatch 6.7% vs. 15.6%, p=0.003). This difference in the general population was far more marked in the obese population. When considering only the non-obese population, the difference is no longer significant, which is why the general population results are tainted at the expense of the obese. 

At least at one year, the mismatch had no impact in cardiovascular mortality, or functional class.

Conclusion

The self-expandable valve was associated to lower mismatch rate vs. the balloon expandable valve regardless annulus area. This difference was basically driven by the group of larger patients with greater body surface (body mass >1.83 m²).

Original Title: Prosthesis-Patient Mismatch Following Transcatheter Aortic Valve Replacement With Supra-Annular and Intra-Annular Prostheses.

Reference: Taishi Okuno et al. J Am Coll Cardiol Intv 2019, article in press.



Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

TAVR in Small Annuli: What Valve Should We Use?

One of the major challenges of severe aortic stenosis are patients with small aortic annuli, defined as ≤430 mm² aortic valve area. This condition...

ACC 2025 | TAVI in Low-Risk Patients: 5-Year Outcomes of EVOLUTE LOW RISK

Transcatheter aortic valve implantation (TAVI) is a valid alternative to surgery in low-risk patients with severe aortic stenosis. However, one of its main limitations...

ACC 2025 | BHF PROTECT-TAVI: Are Cerebral Protection Systems Necessary in TAVI?

TAVI has seen a steady increase in use, though stroke continues to be one of its unwanted complications, mostly ischemic and, less frequently, hemorrhagic. The...

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

TAVR in Small Annuli: What Valve Should We Use?

One of the major challenges of severe aortic stenosis are patients with small aortic annuli, defined as ≤430 mm² aortic valve area. This condition...

Patients at High Risk of Bleeding After Coronary Angioplasty: Are Risk Assessment Tools ARC-HBR and PRECISE-DAPT Useful?

Patients undergoing coronary stenting typically receive dual antiplatelet therapy (DAPT) for 6 to 12 months, consisting of a P2Y12 receptor inhibitor and aspirin. While DAPT...

ACC 2025 | WARRIOR: Ischemia in Women with Non-Obstructive Coronary Artery Disease

Approximately half of all women with symptomatic ischemia who undergo coronary angiography are found to have non-obstructive coronary artery disease ((ischemia and non-obstructive coronary...